These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20653912)

  • 1. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab.
    Elisa B; Beny L
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):442-3. PubMed ID: 20653912
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of infliximab in patients suffering from inflammatory bowel disease.
    Felley C; Michetti P
    Digestion; 2004; 70(1):1-2. PubMed ID: 15297772
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.
    Rossetti S; Actis GC; Fadda M; Rizzetto M; Palmo A
    Dig Liver Dis; 2004 Jun; 36(6):426-31. PubMed ID: 15248385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor therapy for ulcerative colitis.
    Kountouras J; Zavos C; Chatzopoulos D
    Gastroenterology; 2005 Sep; 129(3):1138-9. PubMed ID: 16143158
    [No Abstract]   [Full Text] [Related]  

  • 6. [Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis].
    Hejazi R; Colombel JF; Peyrin-Biroulet L
    Gastroenterol Clin Biol; 2008 Feb; 32(2):162-3. PubMed ID: 18387427
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab for ulcerative colitis following liver transplantation.
    Lal S; Steinhart AH
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):277-80. PubMed ID: 17301656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disseminated salmonella infection with aortic mycotic aneurysm in a ulcerative colitis patient treated with infliximab].
    Corberand D; Bredin C; Gizard E; Sava C; Rey P
    Presse Med; 2013 Dec; 42(12):1658-60. PubMed ID: 23688701
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula.
    Hassan C; Zullo A; Ierardi E; Burattini O; De Francesco V; Morini S
    Gut; 2006 Apr; 55(4):589-90. PubMed ID: 16531548
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.
    Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C
    Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7(2):89-93. PubMed ID: 11383596
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab in ulcerative colitis.
    Böcker U
    Scand J Gastroenterol; 2006 Sep; 41(9):997-1000. PubMed ID: 16938710
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 16. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P
    Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
    Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe neutropenia following infliximab treatment in a child with ulcerative colitis.
    Sherlock ME; Bandsma R; Ota K; Kirby-Allen M; Griffiths AM
    Inflamm Bowel Dis; 2011 Feb; 17(2):E17-8. PubMed ID: 20824816
    [No Abstract]   [Full Text] [Related]  

  • 20. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
    Reenaers C; Belaiche J; Louis E
    Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.